Funding · Pre-seed · 1 October 2026

Smi Drug Discovery raises £151k

Smi Drug Discovery, a healthtech company based in Cambridge, issued 44,364 new shares at £3.40 each on 1 October, according to its Companies House filing. That adds up to £151k of new capital. At that share price, the indicative valuation after the round is about £33.1m. Investors have not been named in the filing yet.

✓ Verified · official record, 4 Nov 2026. What this means

£151kNew capital
£3.40Price per share
£33.1mIndicative valuation after the round
6thRound size percentile, 32 pre-seed rounds
0.5%New shares as share of company
Filing-verified
CompanySmi Drug Discovery
StagePre-seed
SectorHealthTech
Based inCambridge
Shares issued44,364 of 9,730,505 in issue
InvestorsNot named in the filing yet
SourceCompanies House filing · confidence highView source ↗

How we work this out: the amount is the number of new shares multiplied by the price paid for each one, as reported on the SH01 filing. The valuation is that price multiplied by every share in issue afterwards. It's indicative only: it ignores options and convertible notes, some rounds are filed in more than one tranche, and companies can hide it. Methodology

Company record · Companies House
Company number11175710 ↗
Incorporated29 January 2018 (8.8 years old)
Accounts filedSmall company (turnover under £15m)
DirectorsRonald Andrews, James John Clark, John, Dr Hirst, Stephen Little, Andrew James, Dr Thompson
Secured lendingNone registered
Your note on Smi Drug Discovery

Sign in to keep private notes on this company.

If this is your company

Hide the valuation estimate straight away, add your investors, or tell us something's wrong. We check every change.